KR20180029579A - Facial mask - Google Patents
Facial mask Download PDFInfo
- Publication number
- KR20180029579A KR20180029579A KR1020160117815A KR20160117815A KR20180029579A KR 20180029579 A KR20180029579 A KR 20180029579A KR 1020160117815 A KR1020160117815 A KR 1020160117815A KR 20160117815 A KR20160117815 A KR 20160117815A KR 20180029579 A KR20180029579 A KR 20180029579A
- Authority
- KR
- South Korea
- Prior art keywords
- angelica
- facial mask
- ginseng
- pearl powder
- present
- Prior art date
Links
- 230000001815 facial effect Effects 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 239000000843 powder Substances 0.000 claims abstract description 26
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 21
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 21
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 21
- 235000008434 ginseng Nutrition 0.000 claims abstract description 21
- 244000018633 Prunus armeniaca Species 0.000 claims abstract description 19
- 235000009827 Prunus armeniaca Nutrition 0.000 claims abstract description 19
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 4
- 241000132012 Atractylodes Species 0.000 claims abstract description 4
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 4
- 241000125175 Angelica Species 0.000 claims description 20
- 241000208340 Araliaceae Species 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 19
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 15
- 235000021419 vinegar Nutrition 0.000 claims description 14
- 239000000052 vinegar Substances 0.000 claims description 14
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 11
- 239000000600 sorbitol Substances 0.000 claims description 11
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 6
- 239000011574 phosphorus Substances 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 108010068370 Glutens Proteins 0.000 claims description 2
- 235000021312 gluten Nutrition 0.000 claims description 2
- 239000001944 prunus armeniaca kernel oil Substances 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 244000284012 Vetiveria zizanioides Species 0.000 claims 1
- 235000007769 Vetiveria zizanioides Nutrition 0.000 claims 1
- 210000000416 exudates and transudate Anatomy 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 239000002341 toxic gas Substances 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 239000002699 waste material Substances 0.000 abstract description 2
- 240000002045 Guettarda speciosa Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 29
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 8
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 8
- 229960004502 levodopa Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000002752 melanocyte Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000219873 Vicia Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- -1 potassium ferricyanide Chemical compound 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D44/00—Other cosmetic or toiletry articles, e.g. for hairdressers' rooms
- A45D44/002—Masks for cosmetic treatment of the face
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D44/00—Other cosmetic or toiletry articles, e.g. for hairdressers' rooms
- A45D44/22—Face shaping devices, e.g. chin straps; Wrinkle removers, e.g. stretching the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 피부 보호 분야, 특히 페이셜 마스크(facial mask) 분야에 관한 것이다.The present invention relates to the field of skin protection, in particular to the field of facial mask.
얼굴은 다른 신체 부위보다 주위 환경에 더 쉽게 노출되고, 이에 따라 더욱 자주 바람, 일광화상, 전자기선, 오염 등에 의한 영향으로 인해 고생한다. 사람마다 다양한 피부 성질로 인해, 몇몇 피부 문제들이 일어날 수 있고, 여기에 연루된 사람들은 당혹감 또는 불편함을 느낄 수 있다. 더욱 심각하게도, 이러한 문제들이 사람들의 일, 결혼 등에 좋지 않은 영향을 미칠 수 있다.The face is more easily exposed to the surrounding environment than the other body parts, and thus more frequently suffered from the effects of wind, sunburn, electromagnetic radiation, pollution, and the like. Due to the different skin properties of each person, some skin problems can arise, and those involved can feel embarrassed or uncomfortable. More seriously, these problems can have a negative impact on people's work, marriage, and so on.
페이셜 마스크는 얼굴의 문제를 경감시키거나 없애는데 매우 일반적이다. 하지만, 많은 페이셜 마스크는 중금속 또는 인 분말 성분을 함유하고, 이 성분들은 장시간 동안 페이셜 마스크를 사용한다면 사람들의 피부를 손상시킬 수 있다.Facial masks are very common for alleviating or eliminating facial problems. However, many facial masks contain heavy metal or phosphorus ingredients, which can damage people's skin if they use facial masks for extended periods of time.
따라서, 천연의 안전한 성분을 보유하여 장시간 사용에 적당하면서 피부에 상처를 덜 주는 페이셜 마스크의 개발이 필요하다.Therefore, it is necessary to develop a facial mask which has a natural safe ingredient and which is suitable for long-time use and less damaging to the skin.
본 발명의 목적은 얼굴 보호에 안전하고 효과적인 페이셜 마스크를 제공하는 것이다.It is an object of the present invention to provide a facial mask that is safe and effective for face protection.
본 발명의 한 관점에 따르면, 중량부(weight parts) 기준으로, 인삼 2 내지 8, 진주 분말 2 내지 8, 구릿대(Angelica dahurica) 1 내지 4, 백작약(radices paeoniae alba) 1 내지 5, 백출(white atractylodes rhizome) 3 내지 7, 살구씨유(apricot kernel) 3 내지 7, 안젤리카(angelica) 1 내지 5, 의이인(coix seed) 3 내지 7을 함유하는, 페이셜 마스크가 제공된다.According to one aspect of the present invention there is provided a pharmaceutical composition comprising, on a weight parts basis, ginseng 2 to 8, pearl powder 2 to 8, Angelica dahurica 1 to 4, radices paeoniae alba 1 to 5, white (white) atractylodes rhizome 3 to 7, apricot kernel 3 to 7, angelica 1 to 5, and coix seeds 3 to 7.
본 발명의 유익한 효과는 전통 한약 원료가 서로 상호작용하여 상승작용 효과가 있고, 얼굴 혈액 순환이 가속화되고 노폐물과 독가스가 흡수될 수 있다는 것이다.The beneficial effect of the present invention is that the traditional herbal ingredients interact with each other to have a synergistic effect, accelerate the face circulation, and absorb waste and poison gas.
전통 한약 페이셜 마스크는 영양 물질과 유효 물질이 용이하게 피부 심층까지 침투하도록 하고, 나아가 보습, 피부 수분보충(moistening), 미백, 기미제거, 주름 방지, 노화방지, 소염, 독소 제거 및 여드름방지 역할을 한다.Traditional Korean medicine facial masks are designed to make nutrients and active substances easily penetrate deep into the skin and further serve as moisturizing, moisturizing, whitening, anti-wrinkle, anti-wrinkle, anti-aging, anti-inflammatory, do.
또한, 본 발명에 의해 제공되는 페이셜 마스크 중의 다양한 성분들은 상호작용을 하여 긴 품질 보증 기간을 제공한다.In addition, the various components in the facial mask provided by the present invention interact to provide a long quality assurance period.
마지막으로, 본 발명에 의해 제공되는 페이셜 마스크는 오로지 천연 식물을 함유하고 어떠한 화학적 성분도 포함하지 않는다. 따라서, 본 발명은 사람들의 피부에 건강함을 주고 거의 손상을 주지 않는다.Finally, the facial mask provided by the present invention contains only natural plants and does not contain any chemical components. Therefore, the present invention gives healthiness to people's skin and hardly causes damage.
이하의 예들은 본 발명의 범위에 속하는 양태들을 설명하고 입증하는 것이다. 이 예들은 단지 예시를 목적으로 하고, 이의 다양한 변형들이 본 발명의 취지와 범위에서 벗어남이 없이 가능한 바, 본 발명을 제한하는 것으로 해석되지 않아야 한다.The following examples illustrate and demonstrate aspects falling within the scope of the present invention. These examples are for illustrative purposes only, and various modifications thereof are possible without departing from the spirit and scope of the invention, and should not be construed as limiting the invention.
본 발명의 한 관점에 따르면, 중량부(weight parts) 기준으로, 인삼 2 내지 8, 진주 분말 2 내지 8, 구릿대(Angelica dahurica) 1 내지 4, 백작약(radices paeoniae alba) 1 내지 5, 백출(white atractylodes rhizome) 3 내지 7, 살구씨유(apricot kernel) 3 내지 7, 안젤리카(angelica) 1 내지 5, 의이인(coix seed) 3 내지 7을 함유하는, 페이셜 마스크 조성물이 제공된다.According to one aspect of the present invention there is provided a pharmaceutical composition comprising, on a weight parts basis, ginseng 2 to 8, pearl powder 2 to 8, Angelica dahurica 1 to 4, radices paeoniae alba 1 to 5, white (white) atractylodes rhizome 3 to 7, apricot kernel 3 to 7, angelica 1 to 5, and coix seeds 3 to 7.
본 발명의 제1 양태에 따르면, 이 페이셜 마스크 조성물은 중량부 기준으로 인삼 2, 진주 분말 2, 구릿대 1, 백작약 1, 백출 3, 살구씨유 3, 안젤리카 1, 의이인 3을 함유한다.According to the first aspect of the present invention, the facial mask composition contains ginseng 2, pearl powder 2, peel 1, vinegar 1, extract 3, apricot seed oil 3, angelica 1, and phosphorus 3 on a weight basis.
본 발명의 제2 양태에 따르면, 이 페이셜 마스크 조성물은 중량부 기준으로 인삼 8, 진주 분말 8, 구릿대 4, 백작약 5, 백출 7, 살구씨유 7, 안젤리카 5, 의이인 7을 함유한다.According to the second aspect of the present invention, the facial mask composition contains ginseng 8, pearl powder 8, sorbitol 4, vinegar 5, extract 7, apricot seed oil 7, angelica 5,
본 발명의 제3 양태에 따르면, 이 페이셜 마스크 조성물은 중량부 기준으로 인삼 2, 진주 분말 8, 구릿대 1, 백작약 5, 백출 3, 살구씨유 7, 안젤리카 1, 의이인 7을 함유한다.According to a third aspect of the present invention, the facial mask composition contains, on a weight basis, ginseng 2, pearl powder 8, sorbitol 1, vinegar 5, extract 3, apricot seed oil 7, angelica 1,
본 발명의 제4 양태에 따르면, 이 페이셜 마스크 조성물은 중량부 기준으로 인삼 8, 진주 분말 2, 구릿대 4, 백작약 1, 백출 7, 살구씨유 3, 안젤리카 5, 의이인 3을 함유한다.According to a fourth aspect of the present invention, the facial mask composition contains ginseng 8, pearl powder 2, peel 4, vinegar 1, extract 7, apricot seed oil 3, angelica 5, and phosphorus 3 on a weight basis.
본 발명의 제5 양태에 따르면, 이 페이셜 마스크 조성물은 중량부 기준으로 인삼 5, 진주 분말 5, 구릿대 2.5, 백작약 2.5, 백출 5, 살구씨유 5, 안젤리카 3, 의이인 5를 함유한다.According to the fifth aspect of the present invention, the facial mask composition contains ginseng 5, pearl powder 5, gluten 2.5, vetch 2.5, exorcism 5, apricot kernel oil 5, angelica 3, and phosphorus 5 on a weight basis.
본 발명의 제6 양태에 따르면, 이 페이셜 마스크 조성물은 중량부 기준으로 인삼 2, 진주 분말 5, 구릿대 1, 백작약 3, 백출 3, 살구씨유 5, 안젤리카 1, 의이인 5를 함유한다.According to a sixth aspect of the present invention, the facial mask composition contains, on a weight basis, ginseng 2, pearl powder 5, sorbitol 1, vinegar 3, extract 3, apricot seed oil 5, angelica 1,
본 발명의 제7 양태에 따르면, 이 페이셜 마스크 조성물은 중량부 기준으로 인삼 8, 진주 분말 5, 구릿대 4, 백작약 3, 백출 7, 살구씨유 5, 안젤리카 5, 의이인 5를 함유한다.According to a seventh aspect of the present invention, the facial mask composition contains ginseng 8, pearl powder 5, sorbitol 4, vinegar 3, extract 7, apricot seed oil 5, angelica 5,
본 발명의 제8 양태에 따르면, 이 페이셜 마스크 조성물은 중량부 기준으로 인삼 5, 진주 분말 2, 구릿대 2.5, 백작약 1, 백출 5, 살구씨유 3, 안젤리카 3, 의이인 3을 함유한다.According to the eighth aspect of the present invention, the facial mask composition contains, on a weight basis, ginseng 5, pearl powder 2, sorbitol 2.5, vinegar 1, extract 5, apricot seed oil 3, angelica 3,
본 발명의 제9 양태에 따르면, 이 페이셜 마스크 조성물은 중량부 기준으로 인삼 5, 진주 분말 8, 구릿대 2.5, 백작약 5, 백출 5, 살구씨유 7, 안젤리카 3, 의이인 7을 함유한다. According to a ninth aspect of the present invention, the facial mask composition contains, on a weight basis, ginseng 5, pearl powder 8, sorbitol 2.5, vinegar 5, extract 5, apricot seed oil 7, angelica 3,
본 발명의 제10 양태에 따르면, 이 페이셜 마스크 조성물은 중량부 기준으로 인삼 6, 진주 분말 6, 구릿대 2, 백작약 2, 백출 4, 살구씨유 4, 안젤리카 2, 의이인 4를 함유한다.According to a tenth aspect of the present invention, the facial mask composition contains, on a weight basis, ginseng 6, pearl powder 6, sorbitol 2, vinegar 2, extract 4, apricot seed oil 4, angelica 2,
본 발명의 제11 양태에 따르면, 이 페이셜 마스크 조성물은 중량부 기준으로 인삼 7, 진주 분말 7, 구릿대 3, 백작약 4, 백출 6, 살구씨유 6, 안젤리카 4, 의이인 6을 함유한다.According to an eleventh aspect of the present invention, the facial mask composition contains ginseng 7, pearl powder 7, sorbitol 3, vinegar 4, extract 6, apricot seed oil 6, angelica 4,
본 발명의 제12 양태에 따르면, 이 페이셜 마스크 조성물은 중량부 기준으로 인삼 6, 진주 분말 4, 구릿대 2, 백작약 3, 백출 4, 살구씨유 5, 안젤리카 2, 의이인 4를 함유한다.According to a twelfth aspect of the present invention, the facial mask composition contains, on a weight basis, ginseng 6, pearl powder 4, sorbitol 2, vinegar 3, extract 4, apricot seed oil 5, angelica 2,
본 발명의 제13 양태에 따르면, 이 페이셜 마스크 조성물은 중량부 기준으로 인삼 7, 진주 분말 3, 구릿대 3, 백작약 2, 백출 6, 살구씨유 4, 안젤리카 4, 의이인 4를 함유한다.According to a thirteenth aspect of the present invention, the facial mask composition contains ginseng 7, pearl powder 3, peel 3, vetch 2, peel 6, apricot seed oil 4, angelica 4, and phosphorus 4 on a weight basis.
특히, "중량부"란 용어는 각 성분들 간의 비(ratio)를 의미하는 것이지, 전체 중량 대비 백분율을 의미하는 것이 아님을 밝히는 바이다.In particular, the term "parts by weight " refers to the ratio between the components, not to the percentage by weight.
본 발명의 유익한 효과는 전통 한약 원료가 서로 상호작용할 수 있어 상승작용 효과를 나타내고, 얼굴 혈액 순환이 가속화될 수 있으며 노폐물과 독가스가 흡수될 수 있다는 것이다.The beneficial effect of the present invention is that the traditional herbal ingredients can interact with each other, exhibit a synergistic effect, accelerate the blood circulation in the face, and absorb wastes and poison gas.
제조 방법Manufacturing method
전술한 재료 또는 성분들은 시중에서 구입할 수 있고, 또는 통상의 가공처리 방법으로 수득할 수 있으며, 예컨대 이 재료들은 재료를 건조하고 평균 입자 크기 범위가 20 내지 30 메시(mesh)인 분말로 분쇄하여 수득할 수 있다.The above-mentioned materials or components are commercially available or can be obtained by conventional processing methods. For example, these materials are obtained by drying the material and pulverizing it into a powder having an average particle size range of 20 to 30 mesh can do.
전통 한약 추출물의 제법은 다음과 같은 작업을 포함한다.The preparation of traditional Chinese medicine extract includes the following tasks.
각 성분들을 혼합하여 분말로 마쇄하고 용매로써 에탄올을 이용하여 분말에 초임계 이산화탄소 추출을 60℃, 30MPa 하에 0.5시간 동안 수행한다. 특히, 에탄올의 양은 상기 분말 g당 2ml이고, 분석 압력은 10MPa이며 분석 온도는 20℃이다.Each of the components is mixed and pulverized into powder, and supercritical carbon dioxide extraction is carried out at 60 DEG C under 30 MPa for 0.5 hour by using ethanol as a solvent. In particular, the amount of ethanol is 2 ml per g of the powder, the analytical pressure is 10 MPa, and the analysis temperature is 20 캜.
감압 농축 및 에탄올 회수를 수행하여 에탄올 추출물 농축액을 수득한다.Concentration under reduced pressure and ethanol recovery were carried out to obtain an ethanol extract concentrate.
초임계 이산화탄소 추출 후 잔류물을 2회 비등시키는데, 잔류물의 1차 비등은 8 내지 10배의 물로 30 내지 50분 동안 비등시키고, 잔류물의 2차 비등은 9 내지 12배의 물로 80 내지 90분 동안 비등시킨다.After the supercritical carbon dioxide extraction, the residue is boiled twice, the primary boiling of the residue is boiled with 8 to 10 times of water for 30 to 50 minutes, the secondary boiling of the residue is carried out with 9 to 12 times of water for 80 to 90 minutes Boil.
비등된 액체를 여과하고, 여과액을 합한 뒤, 밀도가 50℃에서 1.3 내지 1.5 사이인 액체로 농축시킨다.The boiled liquid is filtered and the filtrates are combined and then concentrated to a liquid having a density between 1.3 and 1.5 at 50 캜.
밀도가 1.3 내지 1.5 사이인 액체를 건조하여 추출물을 수득한다.A liquid having a density between 1.3 and 1.5 is dried to obtain an extract.
거대다공성 흡착 수지를 이용하여 이 추출물을 농축시킨다. 구체적으로, 추출물은 특정 양의 물로 희석하고, 동일한 부피의 D-101 거대다공성 흡착 수지와 혼합한 뒤, D-101 또는 AB-8형 및 다른 비극성, 약한 극성 또는 중간 극성의 거대다공성 흡착 수지 위에 부하한다. 부하 부피는 생산 부피 대 수지 간의 비율이 1:3이 되게 계산한다. 15분간 정치식 흡착 후, 다른 밀도를 가진 10배 용량의 에탄올을 사용하여 용출을 수행하고, 에탄올 용출 용액 60 내지 70%를 수집하여 갈색 분말을 수득한다.The extract is concentrated using a macroporous adsorbent resin. Specifically, the extract is diluted with a certain amount of water, mixed with the same volume of D-101 macroporous adsorbent resin, then mixed with D-101 or AB-8 and other non-polar, macroporous or intermediate polar macroporous adsorbent resins Load. The load volume is calculated so that the ratio between production volume and resin is 1: 3. After the adsorption step for 15 minutes, elution was carried out using a 10-fold volume of ethanol with different densities, and 60-70% of the ethanol eluting solution was collected to obtain a brown powder.
또한, 이 분말을 초임계 이산화탄소 추출을 통해 수득한 갈색 오일 유사 점액과 혼합하여 전통의 한약 추출물을 수득한다.In addition, this powder is mixed with brown oil-like mucilage obtained through supercritical carbon dioxide extraction to obtain a traditional herbal medicine extract.
UVB에 의해 유도된 안료 모델을 이용하고, 전통 한약을 다음과 같이 투여한다.Using a UVB-induced pigment model, traditional herbal medicine is administered as follows.
각 기니아 피그 등에서 분리된 세 영역(2cm x 2cm)을 선택하고, 각 기니아 피그의 등에서 긴 털은 가위로 자르고 짧은 털은 전기면도기로 제거한다. 그 뒤, 상기 영역들을 310-315nm 사이에 스펙트럼 피크를 가진 UVB 광원이 장착된 SS-04B형 광치료 장치로 광조사했다. 상기 영역은 200mJ/㎠의 양으로 매일 20분 동안 광조사하고, 이 광조사는 2주 동안 지속하여 누적된 광조사량이 2800mJ/㎠이게 한다. 한약은 광조사가 끝나고 2시간 후에 투여하고, 한약 투여는 광조사가 끝난 후 2주 동안 지속한다. 그 다음, 얼굴 조직을 병리학적 조사를 위해 채취한다.Three regions (2 cm x 2 cm) separated from each guinea pig are selected, and long hairs are cut with scissors on each guinea pig's back, and short hairs are removed with an electric shaver. Thereafter, the regions were irradiated with light with a SS-04B type light-treating device equipped with a UVB light source having a spectral peak between 310-315 nm. The area is irradiated with light in an amount of 200 mJ / cm 2 for 20 minutes every day, and this light irradiation lasts for 2 weeks, resulting in an accumulated light irradiation amount of 2800 mJ / cm 2. The Chinese medicine is administered 2 hours after the light irradiation, and the Chinese medicine application is continued for 2 weeks after the light irradiation. The facial tissue is then harvested for pathological examination.
샘플은 멜라닌 함유 세포 수 및 DOPA 양성 세포 수를 관찰하기 위하여 3가지 그룹으로 나눈다.The samples are divided into three groups to observe the number of melanin-containing cells and the number of DOPA-positive cells.
그룹 1: UVB 광조사를 받지 않은 정상 기니아 피그의 등 피부를 함유하는 대조군;Group 1: control group containing the back skin of normal guinea pigs not exposed to UVB light;
그룹 2: UVB 광조사를 받지만 본 발명의 전통 한약으로 코팅되지 않은 기니아 피그의 등 피부를 함유하는 그룹;Group 2: a group containing back skin of guinea pigs that have been exposed to UVB light but are not coated with the traditional herbal medicine of the present invention;
그룹 3: UVB 광조사 후 양태 1 내지 13의 전통 한약을 각각 0.5 및 1mg/ml 농도로 코팅한 기니아 피그의 등 피부를 함유하는 그룹.Group 3: A group containing back skin of guinea pigs coated with 0.5 and 1 mg / ml of traditional herbal medicine of Examples 1 to 13 after irradiation with UVB light.
염색 공정Dyeing process
1) HE 염색 : 기니아 피그의 등 피부 샘플(2cm x 2cm)을 종래의 파라핀 절편을 이용하여 HE 염색한다.1) HE staining: HE stain skin samples (2 cm x 2 cm) of guinea pigs using conventional paraffin sections.
2) 슈몰(Schmorl) 염색2) Schmorl dyeing
a. 절편을 물로 세정한다; a. The sections are rinsed with water;
b. 그 다음, 절편을 0.04mol/L 농도의 FeCl3 용액 40ml, 0.04mol/L 농도의 페리시안화칼륨 용액 6ml 및 증류수 6ml의 혼합물로 10분 동안 처리한다;b. The slice is then treated with a mixture of 40 ml of a 0.04 mol / L FeCl 3 solution, 6 ml of a 0.04 mol / L potassium ferricyanide solution and 6 ml of distilled water for 10 minutes;
c. 절편을 그 다음 흐르는 물로 세정한다. c. The slice is then rinsed with running water.
결과: 멜라닌 세포가 갈색 및 흑색 입자로 염색된다.Results: Melanocytes were stained with brown and black particles.
3) 이모카와(Imokawa) 염색3) Dyeing of Imokawa
a. 피부 샘플(2cm x 2cm)을 기니아 피그의 등에서 채취하고, 0.1mol/L(pH 6.8) 농도의 PBS 액체로 세정한 다음, 1mol/L 농도의 브롬화나트륨과 37℃에서 5시간 동안 항온처리한다. a. Skin samples (2 cm x 2 cm) are collected from guinea pigs, washed with PBS liquid at a concentration of 0.1 mol / L (pH 6.8), and incubated with sodium bromide at a concentration of 1 mol / L for 5 hours at 37 ° C.
b. 피부의 각피와 진피를 분리한다. b. Separate the dermis and dermis of the skin.
c. 각피는 3.33mol/L(10%) 농도의 냉각된 중성 포르말린 용액으로 30분 동안 조절하고, 그 다음 0.1mol/L(pH 6.8) 농도의 PBS 용액으로 2회 세정한다. c. The corn flakes are conditioned for 30 minutes in a cold neutral formalin solution at a concentration of 3.33 mol / L (10%) and then washed twice with 0.1 mol / L (pH 6.8) of PBS solution.
d. 그 다음, 각피는 0.1mol/L 농도의 PBS 용액으로 5시간 동안 염색한다. d. Then, the corn flakes are stained with a 0.1 mol / L PBS solution for 5 hours.
결과: 멜라닌 세포가 흑색 및 갈색 입자로 염색된다.Results: Melanocytes stained with black and brown particles.
광학현미경 관찰Optical microscope observation
1) 멜라닌 입자 세포의 계수: 슈몰 염색을 진행하고, 멜라닌 입자 세포 수를 각 샘플의 각피 기재 1㎟ 마다 고배율 렌즈하에 Net 접안렌즈 마이크로미터 단일 맹검 방법으로 계수한다.1) Coefficient of Melanin Particle Cells: Proceed with smoothing and number of melanin particles is counted by a Net eyepiece micrometer single-blind method under a high magnification lens every 1 mm 2 of the cornea of each sample.
2) DOPA 양성 세포의 계수: 이모카와 염색을 진행하고, DOPA 양성 멜라닌 세포의 수를 각 샘플의 각피 기재 1㎟ 마다 고배율 렌즈하에 Net 접안렌즈 마이크로미터 단일 맹검 방법으로 계수한다. 2) Coefficient of DOPA positive cells: Imokawa staining is carried out, and the number of DOPA positive melanocytes is counted by a Net eyepiece micrometer single-blind method under a high magnification lens every 1 mm 2 of the cornea of each sample.
표 1은 광조사하지 않은 그룹 및 본 발명의 양태 1 내지 13에 따른 페이셜 마스크가 적용된 그룹과 관련하여 멜라닌 입자 세포 및 DOPA 양성 멜라닌 세포의 평균 수를 나타낸 것이다.Table 1 shows the average number of melanin particle and DOPA positive melanocyte cells in relation to the unirradiated group and the group to which the facial mask according to Embodiments 1 to 13 of the present invention was applied.
대조군과 비교 시, UVB 광조사에 노출된 제2 그룹은 훨씬 많은 수의 멜라닌 입자 세포 및 DOPA 양성 멜라닌 세포를 보유한다.Compared with the control group, the second group exposed to UVB light irradiation has a much larger number of melanin particle cells and DOPA positive melanocyte cells.
본 발명의 양태 1 내지 13을 적용한 후, 각피의 멜라닌 입자 세포 및 DOPA 양성 멜라닌 세포의 수는 대조군과 아주 가까운 수준으로 유의적으로 감소했다. 분명히 본 발명은 피부 미백 및 기미 제거에 양호한 효과를 나타낸다.After applying Embodiments 1 to 13 of the present invention, the number of melanin particle cells and DOPA-positive melanocyte cells of the squamous epithelium was significantly reduced to a level very close to that of the control group. Obviously, the present invention shows a good effect for skin whitening and stain removal.
특히, 양태 5는 멜라닌 입자 세포 및 DOPA 양성 멜라닌 세포 수를 감소시키는 데 있어서 양태 1 내지 13 중에서 가장 효과가 좋고, 때로 이 양태는 대조군과 매우 가까운 수준을 달성한다.Particularly, Embodiment 5 is most effective among the Embodiments 1 to 13 in reducing melanin particle cells and DOPA positive melanin cell number, and sometimes this embodiment achieves a level very close to the control group.
또한, 양태 1, 11 및 12도 역시 양태 1을 제외한 다른 양태에 비해 비교적 우수한 성능을 나타낸다.In addition, Embodiments 1, 11 and 12 also exhibit comparatively excellent performance in comparison with the aspects other than Embodiment 1.
본 발명의 페이셜 마스크는 인체 피부, 특히 얼굴 피부에 국소 적용하기에 적합하다. 본 발명의 사용은 다양한 성분들의 침착 및 침투로 인하여 피부에 평활함, 부드러움 및 보습감과 같은 피부 컨디셔닝 유익을 제공한다.The facial mask of the present invention is suitable for topical application to human skin, especially facial skin. The use of the present invention provides skin conditioning benefits such as skin smoothness, softness and moisturizing due to deposition and penetration of various ingredients.
본 발명의 유익은 본 발명의 마스크 조성물의 적용에 의해 유화된 액체 조성물에 포함된 장기적인 미백제 및 피부 유익제와 같은 특정 유익제에 의거하여 제공된다. 본 발명의 마스크 조성물은 특히 피부에 영양 성분 및 기타 유익제를 전달하는데 유리하다.The benefits of the present invention are provided by a particular benefit agent, such as a long-acting whitening agent and a skin benefit agent, included in the liquid composition emulsified by application of the mask composition of the present invention. The mask composition of the present invention is particularly advantageous for delivering nutrients and other beneficial agents to the skin.
불용성 기재의 사용없이 액체 조성물을 피부에 적용할 때와 비교 시, 장기간 동안의 전달 수단으로써 불용성 기재를 구비한 본 발명의 마스크 조성물의 사용은 상기 제제의 분포 및 침착을 더 좋게 하고, 경피적으로 전달가능한 상기 제제가 더 잘 침투하도록 하는 것으로 생각된다.The use of the inventive mask composition with an insoluble substrate as a means of delivery for a longer period of time, as compared to when applying the liquid composition to the skin without the use of an insoluble substrate, results in better distribution and deposition of the formulation, It is believed that this makes it possible for the agent to penetrate better.
또한, 공기 투과성이 낮은 불용성 기재가 사용되면, 피부에 피부 유익제가 더욱 효과적으로 침투할 것으로 예상된다. 본 발명의 마스크 조성물은 또한 사용 시 사용자에게 청량감 및 편안함과 같은 감정적 유익을 제공할 것으로 생각된다.It is also expected that when an insoluble substrate with low air permeability is used, the skin benefit agent will penetrate more effectively. It is contemplated that the mask composition of the present invention will also provide the user with emotional benefits such as cool sensation and comfort in use.
바람직한 한 양태에 따르면, 마스크 조성물은 (a) 얼굴 피부 면적의 대부분에 마스크 조성물을 적용하는 단계; (b) 이 마스크 조성물을 이 마스크 조성물의 임의의 일부가 건조될 때까지 그 이상은 아닌 시간 동안 얼굴 피부에 방치하는 단계; (c) 얼굴 피부로부터 마스크 조성물을 제거하는 단계; 및 (d) 얼굴 피부에 남아 있는 나머지 액체 조성물을 제거하는 단계를 통해 얼굴 피부를 치료하는데 사용된다.According to a preferred embodiment, the mask composition comprises (a) applying a mask composition to a majority of the facial skin area; (b) leaving the mask composition on the facial skin for a period of time not further than an optional portion of the mask composition being dried; (c) removing the mask composition from the facial skin; And (d) removing the remaining liquid composition remaining on the facial skin.
마스크 조성물은 수성 액체 조성물에 침지되어 있어, 피부에 천천히 놓으면 마스크가 얼굴 피부에 잘 맞는다. 더 잘 맞추고 영양 성분과 기타 피부 유익제가 균일하게 분포하도록 하기 위해, 손가락 끝으로 마스크를 얼굴 피부에 누른다.The mask composition is immersed in an aqueous liquid composition so that when placed slowly on the skin, the mask fits well on the facial skin. Press the mask against the facial skin with your fingertips to better align and distribute the nutrients and other skin benefit agents evenly.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160117815A KR20180029579A (en) | 2016-09-13 | 2016-09-13 | Facial mask |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160117815A KR20180029579A (en) | 2016-09-13 | 2016-09-13 | Facial mask |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180029579A true KR20180029579A (en) | 2018-03-21 |
Family
ID=61900420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160117815A KR20180029579A (en) | 2016-09-13 | 2016-09-13 | Facial mask |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20180029579A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102233384B1 (en) * | 2020-10-14 | 2021-03-26 | 강용찬 | Method of manufacture of mask packs of sea cucumber concentrate |
-
2016
- 2016-09-13 KR KR1020160117815A patent/KR20180029579A/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102233384B1 (en) * | 2020-10-14 | 2021-03-26 | 강용찬 | Method of manufacture of mask packs of sea cucumber concentrate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101991830B1 (en) | Composition for cosmetics comprising glycyrrhiza radix extract and centella asiatica extract using mineral-rich hot spring water as extraction solvent | |
| CN108714126A (en) | Skin care compositions and the preparation method and application thereof with moisturizing and anti-oxidation efficacy | |
| CN108014041A (en) | A kind of anti-ultraviolet composition of plant extracts and preparation method thereof | |
| KR20180029578A (en) | Facial mask | |
| KR101854840B1 (en) | Mask pack comprising pozzolan | |
| CN106726993B (en) | Chinese medicine hair cream and preparation method | |
| KR20180029579A (en) | Facial mask | |
| CN112741795A (en) | Skin-care shower gel containing natural plant extract components and preparation method thereof | |
| KR20170136954A (en) | Facial mask compositions | |
| KR20180065111A (en) | Facial mask | |
| KR20180022430A (en) | Facial mask | |
| KR20180044538A (en) | Facial mask | |
| KR20180033673A (en) | Facial mask | |
| KR20180035371A (en) | Facial mask | |
| KR20180052286A (en) | Facial mask | |
| KR20180000513A (en) | Cosmetics Composition | |
| KR20180016788A (en) | Facial mask | |
| KR20180033859A (en) | Facial mask | |
| KR20180031171A (en) | Facial mask | |
| KR20170136955A (en) | Facial mask | |
| KR20180063599A (en) | Facial mask | |
| KR20180036186A (en) | Facial mask | |
| CN111939107A (en) | Traditional Chinese medicine liquid with beautifying effect | |
| KR20180050028A (en) | Facial mask | |
| DK201600669A1 (en) | Facial mask compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |